Apo-Olanzapine

Olanzapine

Acute & maintenance treatment of schizophrenia & other psychoses where +ve symptoms (eg, delusions, hallucinations, disordered thinking, hostility, & suspiciousness) &/or -ve symptoms (eg, flattened affect, emotional & social w/drawal, poverty of speech) are prominent. Alleviates secondary affective symptoms commonly associated w/ schizophrenia & related disorders. Short-term treatment of acute manic episode & prevention of recurrence of manic, mixed or depressive episodes associated w/ bipolar I disorder.

Schizophrenia 10 mg/day. Manic episode monotherapy Initially 15 mg as a single daily dose. Combination therapy Initially 10 mg daily. Prevention of recurrence in bipolar disorder Initially 10 mg/day. Dose range: 5-20 mg/day at intervals of not <24 hr.

May be taken with or without food: Place in the mouth & allow to disintegrate; it can then be swallowed w/ saliva. Alternatively, disperse in a full glass of water or other beverages (orange juice/apple juice/milk/coffee) immediately prior to taking.

Hypersensitivity. Narrow-angle glaucoma.

Not for the treatment of dementia-related psychosis. Increased prevalence of diabetes in patients w/ schizophrenia. Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia & weakness. Prostatic hypertrophy or paralytic ileus & related conditions. Not recommended in the treatment of dopamine agonist associated psychosis in patients w/ parkinson's disease. Patients w/ elevated ALT &/or AST, signs & symptoms of hepatic impairment, preexisting conditions associated w/ limited hepatic functional reserve & in patients who are being treated w/ potentially hepatotoxic drugs. Discontinue treatment if hepatitis occurs. Patients w/ low leukocyte &/or neutrophil counts, history of drug-induced bone marrow depression/toxicity, patients receiving medicines known to cause neutropenia, bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy, hypereosinophilic conditions or w/ myeloproliferative disease, elderly patients w/ dementia-related psychosis. Discontinue if neuroleptic malignant syndrome occurs. History of seizures or risk factors which may lower seizure threshold. Discontinue or reduce dose if tardive dyskinesia occurs. Combination w/ other centrally-acting drugs & alcohol; drugs known to increase QTc interval especially in the elderly, patients w/ congenital long QT syndrome, CHF, heart hypertrophy, hypokalemia, hypomagnesaemia. Renal &/or hepatic impairment. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn <18 yr.

Wt gain; somnolence, abnormal gait, hallucinations; elevated plasma prolactin levels, high LDL cholesterol. Eosinophilia; increased appetite, elevated glucose levels, fatigue; dizziness, akathisia; orthostatic hypotension; constipation, dry mouth; transient & asymptomatic elevation of hepatic transaminases (ALT/AST); asthenia, oedema; fasting normal to high total cholesterol, triglycerides & glucose, glycosuria.

Metabolism may be induced by smoking & carbamazepine. May inhibit metabolism w/ fluvoxamine. Decreased bioavailability w/ activated charcoal. May antagonise the effects of direct & indirect dopamine agonists. Other CYP1A2 inhibitors eg, ciprofloxacin or ketoconazole.

Antipsychotics

N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics

POM